IDRSF
Idorsia Ltd
Set alert
4.95 USD -0.43 -7.99%
4.40 Day range 4.40
3.82 52-week range 8.19
- YTD
- -5.71%
- 1 year
- +13.27%
- Open
- 4.40
- Prev close
- 5.38
- Mkt cap
- 1.34B
- Vol
- 250
- Avg vol
- 1.60K
- EPS
- -1.74
- P/E
- 0.00
More statistics
- Low
- 4.40
- High
- 4.40
- Earnings
- Oct 29, 2026
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate -0.33437.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | -0.33437 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | -0.24123 | -0.20412 | +0.04 | +15.38% |
| Apr 28, 2026 | Mar 31, 2026 | -0.23148 | -0.17518 | +0.06 | +24.32% |
| Feb 26, 2026 | Dec 31, 2025 | -0.24597 | -0.34058 | -0.09 | -38.46% |
| Oct 30, 2025 | Sep 30, 2025 | -0.27621 | -0.34526 | -0.07 | -25.00% |
| Jul 30, 2025 | Jun 30, 2025 | -0.25208 | -0.07603 | +0.18 | +69.84% |
News
- Idorsia Ltd (IDRSF) Q2 2026 Earnings Call Transcript
- Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon
- Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology
- New analysis of Idorsia's aprocitentan demonstrates significant and sustained reduction in albuminuria in patients with uncontrolled / resistant hypertension
- Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2026
- Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
- Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
- Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
- Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
- Idorsia announces the nomination of three candidates for election to the Board of Directors
Your note
Sign in to keep a note on IDRSF — it syncs with the Stock Master app.